Brokerages Set Sanofi (NASDAQ:SNY) Target Price at $62.67

Sanofi (NASDAQ:SNY) has received a consensus rating of “Buy” from the eleven research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $62.6667.

SNY has been the topic of several research reports. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th.

Sanofi Stock Down 1.0%

SNY stock opened at $50.05 on Friday. The firm has a market capitalization of $122.90 billion, a P/E ratio of 11.72, a P/E/G ratio of 1.38 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94. The company’s 50 day simple moving average is $48.69 and its 200-day simple moving average is $49.53. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.10. The firm had revenue of $14.53 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The company’s revenue for the quarter was down 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.25 EPS. As a group, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Institutional Trading of Sanofi

Several large investors have recently added to or reduced their stakes in SNY. AE Wealth Management LLC boosted its holdings in shares of Sanofi by 13.1% during the 3rd quarter. AE Wealth Management LLC now owns 23,233 shares of the company’s stock worth $1,097,000 after buying an additional 2,696 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Sanofi by 7.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,293 shares of the company’s stock worth $1,288,000 after buying an additional 1,785 shares during the period. EPG Wealth Management LLC boosted its holdings in shares of Sanofi by 10.6% during the 3rd quarter. EPG Wealth Management LLC now owns 19,154 shares of the company’s stock worth $904,000 after buying an additional 1,835 shares during the period. Stablepoint Partners LLC boosted its holdings in shares of Sanofi by 10.2% during the 3rd quarter. Stablepoint Partners LLC now owns 30,388 shares of the company’s stock worth $1,434,000 after buying an additional 2,815 shares during the period. Finally, Paragon Private Wealth Management LLC boosted its holdings in shares of Sanofi by 32.9% during the 3rd quarter. Paragon Private Wealth Management LLC now owns 6,308 shares of the company’s stock worth $298,000 after buying an additional 1,562 shares during the period. 14.04% of the stock is owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.